First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness
Zürich, Switzerland, May 3, 2024 First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness (May 3rd, Seattle, Washington, US) by Dr. Byron Lam (Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA): “First-in-human study to evaluate safety, […]
Two scientific posters were presented on May 8th at ARVO 2024 in Seattle, Washington, US
Zürich, Switzerland, May 8, 2024 Two scientific posters were presented on May 8th at ARVO 2024 in Seattle, Washington, US, with the respective poster titles: “The promotion of visual function regeneration by intravitreal administration of EA-2353 in animal models of photoreceptor degeneration” “Promotion of structural and visual function improvement by intravitreal administration of EA- 2351 […]
Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle,Washington, US.
Zürich, Switzerland, May 4, 2024 Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle, Washington, US.
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, February 6, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on thedevelopment of endogenous regenerative medicines, announced today that the USFood and Drug Administration (FDA) has designated the investigation of EA-2353 forthe treatment of retinitis pigmentosa (RP) as a Fast Track developmentprogram. Fast Track is a process […]
Sven Weiler joins Endogena as VP Medicinal Chemistry
We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022. “I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company […]
Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa
Zürich, Switzerland and Toronto, Canada; 12th July 2022 Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of […]